roa

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN)("CeNeS" or "the Company") the Cambridge-based biopharmaceuticalcompany today announced that a paper published this week in CNSDrugs(1) further supports the hypothesis that acatechol-O-methyltransferase (COMT) inhibitor that acts in thebrain would be a useful agent to address profound cognitivedeficits in schizophrenia and bi...

Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - SirtrisPharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical companyfocused on discovering and developing small molecule drugs to treatdiseases of aging, announced today that activation of SIRT1, amember of the sirtuin family of enzymes, was shown to protectagainst neurodegenerative diseases such as Alzheimer's Disease andAmyotrophic Lat...

Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007

SAN DIEGO, June 19, 2007 /PRNewswire-FirstCall/ -- AmylinPharmaceuticals, Inc. today announced that data featuring itsapproved diabetes drugs, BYETTA(R) (exenatide) injection andSYMLIN(R) (pramlintide acetate) injection, and its pipelinecandidates will be presented at the American Diabetes Association's(ADA) 67th Annual Scientific Sessions being held in Chicago, ILfrom June 22 to 26. The...

First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy

ROANOKE, Va.--(BUSINESS WIRE)--Jun 20, 2007 - Researchers from LunaInnovations Incorporated (NASDAQ: LUNA) and Virginia CommonwealthUniversity (VCU) are the first to show that carbon nanospheres,sometimes referred to as "buckyballs," are able to block allergicresponse in human cell culture experiments and mice. These findingsare described in a paper entitled "Fullerene Nanomaterials Inhibit...

Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -

DOYLESTOWN, Pa., June 20, 2007 /PRNewswire-FirstCall/ -- QuigleyPharma, <a target="_blank" href="http://www.quigleypharma.com/">www.QuigleyPharma.com , a whollyowned subsidiary of The Quigley Corporation announced today that ithas completed a follow-up study to evaluate the impact of QR-443 onlevels of a pro-inflammatory cytokine Interleukin-6 (IL-6) in acachexia model. This new data...

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

Study Results Published in Cancer Research TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCeptCorporation today announced the results of scientific studies that(1) demonstrate that Azixa(TM) (MPC-6827) is effective in treatingmultiple types of human tumors in animal models, (2) reveal amechanism by which MPC-6827 exerts its effects, and (3) show thatMPC-6827 is not affected b...

Studies Show Efficacy and Safety of Alexion's Soliris in Broad Population of PNH Patients

- Data presented at 12th Congress of European Hematology - CHESHIRE, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- AlexionPharmaceuticals, Inc. today announced results from three analysesof Phase III studies examining Soliris(TM) (eculizumab) for thetreatment of paroxysmal nocturnal hemoglobinuria (PNH) at the 12thCongress of European Hematology, organized by The EuropeanHematology Assoc...

Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment

COPENHAGEN, June 3, 2007 - Genmab A/S (CSE: GEN) announcedtoday pre-clinical data illustrating its fully humanHuMax-EGFr™ (zalutumumab) antibody may have broad potentialto treat cancers that over-express several types of EGFr (epidermalgrowth factor receptor). Recently, mutations which appear to alter the signaling abilityof EGFr have been identified in tumors from lung canc...

Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohn's Disease

WASHINGTON--(BUSINESS WIRE)--May 22, 2007 - Alequel(TM), anindividualized oral immune regulation preparation, may be aneffective treatment for moderate-to-severe Crohn's disease. Interimdata from two ongoing double-blind, placebo controlled Phase IIstudies suggest that this investigational approach induced goodclinical remissions and improved patients' quality of life comparedto placebo. Me...

Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases

Celgene to Advance Clinical and Regulatory Development of OralAnti-Inflammatory Franchise SUMMIT, N.J., May 22, 2007 /PRNewswire-FirstCall/ -- CelgeneCorporation announced its plans to advance the development ofleading oral anti-inflammatory candidates across a broad range ofinflammatory diseases. CC-10004 (apremilast), an oral TNFantagonist and anti-inflammatory agent has demonstrated si...

FDA Announces Audio Broadcasts on Emerging Drug Safety Information

ROCKVILLE, Md., April 20,2007-The U.S. Food and DrugAdministration (FDA) is alerting health care professionals andconsumers to the availability of audio broadcasts that provideemerging drug safety information. The broadcasts, commonly known aspodcasts, can be transmitted to personal computers and personalaudio players. The service is part of the agency's ongoing effort to broadena...

Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 3, 2007 - XanthusPharmaceuticals, Inc today presented data demonstrating thatSymadex(TM) reversed the clinical and pathological signs of chronicdisease in an animal model for multiple sclerosis. The presentationwas made by Stephen J. Karlik, Ph.D., Professor of DiagnosticRadiology at the University of Western Ontario, London, Ontario,together with rese...

Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study ofHGS-ETR1 - ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today reported that clinical and preclinicalevidence continues to emerge demonstrating that its TRAIL receptorantibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), havesignificant potential for use in the treatment of a bro...

Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgen's INGN 241

AUSTIN, Texas--(BUSINESS WIRE)--Apr 25, 2007 - IntrogenTherapeutics, Inc. (NASDAQ:INGN) today announced the publication ofnew preclinical data describing how an intrinsic cell survivalpathway impacts the anticancer activity of INGN 241. Inhibition ofthis pathway, known as NF-kB, enhanced the tumor killing effects ofINGN 241 in cell culture and in preclinical models of human tumors.Researche...

Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature

PTC124 Targets Nonsense Mutations; Addresses Underlying Cause ofGenetic Disorders and Restores Protein Function SOUTH PLAINFIELD, N.J., April 23, 2007 /PRNewswire/ -- Newpreclinical data published online in the current edition of thejournal Nature show that PTC124, an investigational new drugdesigned to bypass nonsense mutations, was efficacious in apreclinical model of Duchenne muscular...

Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response

SOUTH SAN FRANCISCO, Calif., April 17, 2007/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immuneresponse data from two previously conducted Phase 2 clinical trialsof GVAX immunotherapy for prostate cancer. Evaluation of antibodyresponses in patients with advanced prostate cancer from thesestudies shows that the GVAX cell-based immunotherapy inducesantibody responses to a bro...

Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer

Scientists to Present Data on Innovative Oncology Compounds at theAmerican Association for Cancer Research Annual Meeting ABBOTT PARK, Ill., April 13, 2007 /PRNewswire-FirstCall/ -- Fordecades, scientists have looked for new therapies that targetcancer. Researchers now know that cancer cells have several uniquecharacteristics -- they require new blood vessels to deliver oxygenand nutrient...

Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility

Research from Non-clinical Studies Presented at the TargetedAnticancer Therapies (TAT 2007) and the Keystone Symposia MolecularTargets for Cancer Meetings Support Phase 1 Trial Design SOUTH SAN FRANCISCO, Calif., March 20, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , presentednon-clinical data on its development-stage compound, SNS-314, attwo leading scientific meetings f...